Company intelligence / Profile preview

OCTIMET Oncology

Beerse, Flanders, Belgiumoctimet.com ↗

Ownership: Private
Employees: ~4
Development stage: Phase 2

Overview

The company has developed OMO-1, an oral MET kinase inhibitor that has shown potent activity in preclinical cancer models, and is developing OMO-2, a dual MET and RAS pathway inhibitor under preclinical investigation for lung cancer[1][3]

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

2 assets

OMO-1

Phase 2

Indications: Lung cancer, Cancer

1 more asset in the full pipeline.

Request access →

Partnerships

Janssen Pharmaceutica (licensed MET kinase inhibitors from them)[2][3]

Beyond the preview

Go deeper on OCTIMET Oncology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OCTIMET Oncology.

Explore the full profile